Organon Expands Australia Biosimilar Partnership With Samsung Bioepis

Organon and Samsung Bioepis have expanded their long-standing partnership to bring a new biosimilar medicine to patients in Australia, strengthening their efforts to improve access to affordable biological treatments while supporting the country’s healthcare system.

Under the expanded Development and Commercialisation Agreement, Organon ANZ will receive exclusive commercial rights to market the new biosimilar in Australia. Samsung Bioepis will continue to be responsible for the medicine’s development, manufacturing and regulatory activities.

The companies did not disclose the name of the biosimilar or the financial terms of the agreement.

The announcement builds on an existing global collaboration between Organon and Samsung Bioepis, which have worked together on several biosimilar products in recent years. Both companies said the latest agreement reflects their shared commitment to increasing patient access to high-quality, lower-cost treatment options.

Biosimilars are medicines that are highly similar to already approved biological drugs. They are designed to provide the same safety, effectiveness and quality as the original biologic medicines but are typically offered at a lower cost. Because of their lower price, biosimilars can increase treatment access for patients while helping healthcare systems reduce spending.

In Australia, biosimilars have become an increasingly important part of the healthcare system. They are widely used in the treatment of conditions such as cancer, autoimmune diseases and inflammatory disorders, giving doctors and patients more treatment options while helping control healthcare costs.

Jinhan Chung, Vice President and Head of Commercial Strategy for International Markets at Samsung Bioepis, said the company is pleased to expand its partnership with Organon and continue making more biosimilars available to Australian patients.

He said the agreement reflects Samsung Bioepis’ long-term commitment to improving global access to biosimilar medicines. Chung added that by maintaining high standards in development, manufacturing and regulatory compliance, the company aims to help more patients receive the treatments they need while contributing to the long-term sustainability of Australia’s healthcare system.

Organon also emphasized the growing importance of biosimilars in Australia’s healthcare landscape.

Martie de Villiers, Biosimilars Business Unit Manager at Organon ANZ, said biosimilars play a vital role in expanding treatment choices for both patients and healthcare professionals. She added that strong partnerships such as the one with Samsung Bioepis are essential to increasing access to these medicines while supporting the financial sustainability of the healthcare system.

According to an analysis of Australia’s Pharmaceutical Benefits Scheme (PBS), biosimilars have already delivered significant cost savings. The report estimated that biosimilars generated approximately AU$1.03 billion in PBS savings between 2015 and 2022.

The same analysis projects that biosimilars could generate an additional AU$3.87 billion in savings between 2023 and 2027, creating opportunities for the government to invest more resources into new and innovative medicines.

Paul Asten, Business Manager for Customer, Trade and Partnerships at Organon ANZ, said the partnership with Samsung Bioepis not only expands patient access to biosimilar medicines but also creates savings that can be reinvested into funding future medical innovations.

He described Samsung Bioepis as one of Organon’s key global collaborators and said the company is proud to strengthen the long-standing relationship through the latest agreement.

Samsung Bioepis is one of the world’s leading developers of biosimilars, with a portfolio covering treatments for several chronic diseases. Organon, a global healthcare company with expertise in women’s health and biosimilars, has continued to expand its biosimilar business through strategic partnerships aimed at increasing access to affordable biological medicines.

The expanded agreement highlights the growing role of biosimilars in modern healthcare as governments seek to balance rising healthcare costs with increasing demand for advanced therapies. By combining Samsung Bioepis’ development and manufacturing capabilities with Organon’s commercial expertise in Australia, the companies aim to improve access to high-quality biologic treatments while supporting the long-term sustainability of the country’s healthcare system.